• 1
    Kaplowitz N. Drug-Induced Liver Injury: Introduction and Overview in Drug-Induced Liver Disease. Kaplowitz N, DeLeve L, eds. New York: Elsevier; 2013, Chapter 1, p 3-14.
  • 2
    Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medication are associated with signicant risk for drug-induced liver injury. HEPATOLOGY 2013; 58: 388-396.
  • 3
    Moylan CA, Suzuki A, Papay JI, Yuen NA, Ames M, Hunt CM. A pre-marketing ALT signal predicts post-marketing liver safety. Regul Toxicol Pharmacol 2012; 63: 433-439.
  • 4
    Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. HEPATOLOGY 2008; 47: 2003-2009.
  • 5
    Hughes JD, Blagg J, Price DA, Bailey S, Decrescenzo GA, Devraj RV, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008; 18: 4872-4875.
  • 6
    Peters JU, Schnider P, Mattei P, Kansy M. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. Chem Med Chem 2009; 4: 680-686.
  • 7
    Waring MJ. Defining optimum lipophilicity and molecular weight ranges for drug candidates. Molecular weight dependent lower logD limits based on permeability. Bioorg Med Chem Lett 2009; 19: 2844-2851.
  • 8
    Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. HEPATOLOGY 2010; 51: 615-20.
  • 9
    Khetani S, Kanchagar C, Krzyzewski C, Krzyzewski S, Moore A, Shi J, et al. Micropatterned co-cultures increase the ability to detect compounds that cause drug induced liver injury in humans over sandwich cultures. Toxicol Sci [published online] 2012.
  • 10
    Porceddu M, Buron N, Roussel C, Labbe G, Fromenty B, Borgne_Sanchez A. Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol Sci 2012; 129: 332-345.
  • 11
    Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 2010; 118: 485-500.
  • 12
    Dawson S, Stahl S, Paul N, Barber J, Kenna JG. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 2012; 40: 130-138.
  • 13
    Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 2011; 10: 292-306.
  • 14
    Monshi M, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, et al. HLA-B*57:01-restricted activation of drug-specific T-cells provides the immunological basis for flucloxacillin-induced liver injury. HEPATOLOGY 2012 [Epub ahead of print].
  • 15
    Norcross M, Luo S, Lu L, Boyne MT, Gomarteli M, Rennels AD, et al. Abacavir induces loading of novel self-peptides into HLA-B*57:01: an auto immune model for HLA-associated drug hypersensitivity. AIDS 2012; 26: F21-F29.
  • 16
    Han D, Hanawa N, Saberi B, Kaplowitz N. Hydrogen peroxide and redox modulation sensitize primary mouse hepatocytes to TNF-induced apoptosis. Free Radic Biol Med 2006; 41: 627-639.
  • 17
    Lou H, Kaplowitz N. Glutathione depletion down-regulates TNFα-induced NF-kB activity via IKK-dependent and independent mechanisms. J Biol Chem 2007; 282: 29470-29481.
  • 18
    Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42: 711-714.